TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway-Reference-Cited by-同舟云学术

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway

Published:2018-04-26 Issue:6 Volume:6 Page:711-722
ISSN:2326-6066
Container-title:Cancer Immunology Research
language:en
Short-container-title:Cancer Immunol Res

Author:

Zizzari Ilaria Grazia,Napoletano Chiara,Botticelli Andrea,Caponnetto Salvatore,Calabrò Fabio^ORCID,Gelibter Alain,Rughetti Aurelia,Ruscito Ilary,Rahimi Hassan,Rossi Ernesto,Schinzari Giovanni,Marchetti Paolo,Nuti Marianna

Funder

Associazione Italiana per la Ricerca sul Cancro (AIRC)

Sapienza Università di Roma (Sapienza University of Rome)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Immunology

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib;Critical Reviews in Oncology/Hematology;2024-10

2. Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab;Immunotherapy;2024-08-19

3. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments;Biochemical Pharmacology;2024-08

4. Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration;Signal Transduction and Targeted Therapy;2024-05-29

5. CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line;Journal of Translational Medicine;2024-04-03